|
Volumn 3, Issue 5, 2001, Pages 322-327
|
Combination calcium channel blocker therapy in the treatment of hypertension
|
Author keywords
[No Author keywords available]
|
Indexed keywords
AMLODIPINE;
AMLODIPINE BESYLATE;
ANGIOTENSIN;
ANGIOTENSIN RECEPTOR ANTAGONIST;
BENAZEPRIL;
BEPRIDIL;
BETA ADRENERGIC RECEPTOR BLOCKING AGENT;
CALAN SR;
CALCIUM CHANNEL BLOCKING AGENT;
CYCLOSPORIN;
CYTOCHROME P450 3A4;
DIHYDROPYRIDINE;
DILTIAZEM;
DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;
DIURETIC AGENT;
ENALAPRIL;
FELODIPINE;
ISRADIPINE;
LACIDIPINE;
MEVINOLIN;
NICARDIPINE;
NIFEDIPINE;
NIMODIPINE;
NISOLDIPINE;
NITRENDIPINE;
RENIN;
SIMVASTATIN;
SPIRONOLACTONE;
VERAPAMIL;
VERELAN PM;
ANGINA PECTORIS;
ARTICLE;
BLOOD PRESSURE REGULATION;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
CORONARY ARTERY DISEASE;
DISEASE MANAGEMENT;
DRUG BINDING;
DRUG BIOAVAILABILITY;
DRUG CLASSIFICATION;
DRUG CONTRAINDICATION;
DRUG METABOLISM;
DRUG POTENCY;
HUMAN;
HYPERTENSION;
PERCEPTION;
RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;
SYMPTOM;
TORSADE DES POINTES;
|
EID: 0034761746
PISSN: 15246175
EISSN: None
Source Type: Journal
DOI: 10.1111/j.1524-6175.2001.00484.x Document Type: Article |
Times cited : (15)
|
References (32)
|